How to Use Python to Teach High School Physics

Annotated Volcano: A Volcano’s Shape Can Tell You How It Will Erupt

FDA places hold on clinical trial of cancer treatment previously reported on KurzweilAI — UPDATE: FDA releases hold
Juno Therapeutics, Inc. announced July 7 that it has received notice from the FDA that it has placed a clinical hold on an immune-cell cancer treatment known as the “ROCKET” trial, which was reported on KurzweilAI on Mar. 10, 2016.
The clinical hold was initiated after two patient deaths, which followed the recent addition of fludarabine to the pre-conditioning regimen. Juno has proposed to the FDA to continue the ROCKET trial using JCAR015 with cyclophosphamide pre-conditioning alone.
Further information on Forbes.
UPDATE JULY 13, 2016: Juno Therapeutics announced Tuesday July 12 that the FDA has removed the hold and “the ROCKET trial will continue enrollment using JCAR015 with cyclophosphamide pre-conditioning only.” In related news, the Law Offices of Howard G. Smith announced an investigation on behalf of investors of Juno Therapeutics, Inc. (NASDAQ: JUNO) concerning the Company and its officers’ possible violations of federal securities laws and noted that “Juno’s share price fell significantly in value, dropping almost 32%.”
Hundreds of mystery human skulls sold on eBay for up to $5500
Watch the first ever footage of wild coral kissing and fighting
US could be set to tackle opioid painkiller epidemic at last
The Psychology of How Pokémon Go Gets Inside Your Brain

